Literature DB >> 11241023

Role of dobutamine echocardiography in detection of myocardial viability for predicting outcome after revascularization in ischemic cardiomyopathy.

R Senior1, A Lahiri.   

Abstract

Coronary artery disease is the most common cause of heart failure in the Western world. Compared with medical therapy, surgical revascularization has been shown to improve survival rates in nonrandomized trials in patients with ischemic cardiomyopathy. However, perioperative mortality is high in this group of patients who do not demonstrate significant viable myocardium. Echocardiography during dobutamine infusion has been shown to reliably detect viable myocardium. Several studies have demonstrated its ability to provide high predictive value for recovery of both regional and global left ventricular function after revascularization. Indeed, nonrandomized studies also have indicated its value in predicting which patients with severe ischemic cardiomyopathy are likely to survive after revascularization. Dobutamine stress echocardiography has emerged as a safe and valuable technique for the assessment of myocardial viability and for the selection of patients for revascularization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241023     DOI: 10.1067/mje.2001.107636

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  3 in total

Review 1.  Diagnostic and imaging considerations: role of viability.

Authors:  Roxy Senior
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

Review 2.  Stress echocardiography in heart failure.

Authors:  Eustachio Agricola; Michele Oppizzi; Matteo Pisani; Alberto Margonato
Journal:  Cardiovasc Ultrasound       Date:  2004-07-30       Impact factor: 2.062

3.  Dobutamine Stress Echocardiography for the Bedside Assessment of Viability Following a Motor Vehicle Accident and Subsequent Myocardial Infarction: A Case Report.

Authors:  Evan L Brittain; Waleed N Irani; Rashid M Ahmad; Ken Monahan
Journal:  Open J Cardiovasc Surg       Date:  2012-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.